
The angle-supported phakic IOL (AcrySof, Alcon Laboratories) is being evaluated for the treatment of moderate to high myopia in three phase II and III clinical trials in Europe and North America enrolling 360 patients. Data from a 3-year visit in 104 eyes show excellent stability, predictability, and vision outcomes with a low rate of adverse events.